vs
Side-by-side financial comparison of HANMI FINANCIAL CORP (HAFC) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
HANMI FINANCIAL CORP is the larger business by last-quarter revenue ($71.2M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs -83.0%, a 112.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 17.1%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 10.4%).
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
HAFC vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.2M | $57.3M |
| Net Profit | $21.2M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 29.8% | -82.2% |
| Net Margin | 29.8% | -83.0% |
| Revenue YoY | 17.1% | 36.9% |
| Net Profit YoY | 20.0% | -9.6% |
| EPS (diluted) | $0.70 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.2M | $57.3M | ||
| Q3 25 | $71.0M | $51.3M | ||
| Q2 25 | $65.2M | $48.5M | ||
| Q1 25 | $62.8M | $32.7M | ||
| Q4 24 | $60.8M | $41.8M | ||
| Q3 24 | $58.5M | $33.3M | ||
| Q2 24 | $56.7M | $29.1M | ||
| Q1 24 | $58.4M | $26.0M |
| Q4 25 | $21.2M | $-47.5M | ||
| Q3 25 | $22.1M | $-52.9M | ||
| Q2 25 | $15.1M | $-46.6M | ||
| Q1 25 | $17.7M | $-49.5M | ||
| Q4 24 | $17.7M | $-43.3M | ||
| Q3 24 | $14.9M | $-43.6M | ||
| Q2 24 | $14.5M | $-32.3M | ||
| Q1 24 | $15.2M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 29.8% | -82.2% | ||
| Q3 25 | 31.1% | -102.6% | ||
| Q2 25 | 23.2% | -93.4% | ||
| Q1 25 | 28.1% | -143.7% | ||
| Q4 24 | 29.1% | -98.6% | ||
| Q3 24 | 25.5% | -132.0% | ||
| Q2 24 | 25.5% | -139.2% | ||
| Q1 24 | 26.0% | -538.7% |
| Q4 25 | 29.8% | -83.0% | ||
| Q3 25 | 31.1% | -103.1% | ||
| Q2 25 | 23.2% | -96.1% | ||
| Q1 25 | 28.1% | -151.4% | ||
| Q4 24 | 29.1% | -103.6% | ||
| Q3 24 | 25.5% | -131.2% | ||
| Q2 24 | 25.5% | -110.9% | ||
| Q1 24 | 26.0% | -544.4% |
| Q4 25 | $0.70 | $-0.73 | ||
| Q3 25 | $0.73 | $-0.82 | ||
| Q2 25 | $0.50 | $-0.75 | ||
| Q1 25 | $0.58 | $-0.81 | ||
| Q4 24 | $0.58 | $-0.71 | ||
| Q3 24 | $0.49 | $-0.73 | ||
| Q2 24 | $0.48 | $-0.55 | ||
| Q1 24 | $0.50 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $796.4M | $139.1M |
| Total Assets | $7.9B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M | ||
| Q1 24 | — | $201.2M |
| Q4 25 | $796.4M | $139.1M | ||
| Q3 25 | $779.5M | $148.8M | ||
| Q2 25 | $762.8M | $-11.9M | ||
| Q1 25 | $751.5M | $18.9M | ||
| Q4 24 | $732.2M | $21.7M | ||
| Q3 24 | $736.7M | $11.2M | ||
| Q2 24 | $707.1M | $39.3M | ||
| Q1 24 | $703.1M | $61.6M |
| Q4 25 | $7.9B | $480.2M | ||
| Q3 25 | $7.9B | $506.9M | ||
| Q2 25 | $7.9B | $372.7M | ||
| Q1 25 | $7.7B | $386.7M | ||
| Q4 24 | $7.7B | $392.3M | ||
| Q3 24 | $7.7B | $363.6M | ||
| Q2 24 | $7.6B | $381.8M | ||
| Q1 24 | $7.5B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.0M | $-25.4M |
| Free Cash FlowOCF − Capex | $203.7M | — |
| FCF MarginFCF / Revenue | 286.2% | — |
| Capex IntensityCapex / Revenue | 3.2% | — |
| Cash ConversionOCF / Net Profit | 9.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.0M | $-25.4M | ||
| Q3 25 | $146.9M | $-26.6M | ||
| Q2 25 | $-19.0M | $-23.3M | ||
| Q1 25 | $25.8M | $-40.4M | ||
| Q4 24 | $52.6M | $-18.8M | ||
| Q3 24 | $6.7M | $-25.2M | ||
| Q2 24 | $2.1M | $-29.1M | ||
| Q1 24 | $30.0M | $-40.7M |
| Q4 25 | $203.7M | — | ||
| Q3 25 | $146.4M | — | ||
| Q2 25 | $-19.6M | — | ||
| Q1 25 | $25.6M | — | ||
| Q4 24 | $49.9M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $29.2M | — |
| Q4 25 | 286.2% | — | ||
| Q3 25 | 206.3% | — | ||
| Q2 25 | -30.0% | — | ||
| Q1 25 | 40.7% | — | ||
| Q4 24 | 82.1% | — | ||
| Q3 24 | 11.1% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 50.0% | — |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 9.70× | — | ||
| Q3 25 | 6.66× | — | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
